Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dean Rudge

Senior Reporter

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data

Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.

Biosimilars Clinical Trials

Lannett Eyes Another $11M In Savings With R&D Sea Change, Job Cuts

Lannett unveiled another round of cost-saving initiatives alongside its financial Q2 earnings, including plans for a radical change for its R&D development.

OTC Drugs Restructuring

Is There A Biosimilar Future For A Smaller Target Like Synagis?

With something of a revolution in the RSV space on the horizon, Generics Bulletin looks at the potential for biosimilar competition in developed markets to AstraZeneca/SOBI’s existing benchmark option, the 25-year-old prophylactic Synagis (palivizumab).

Biosimilars Strategy

What Does Teva’s Exit From PhRMA Suggest About Its Priorities?

Seemingly in one of the first decisions overseen by the company’s new CEO Richard Francis, Teva will not sit at the table of the US brand industry trade association, the Pharmaceutical Research and Manufacturers of America, better known as PhRMA.

Strategy Legislation

Amarin Investor Heat Intensifies, Despite ‘Unprecedented’ Vascepa Fortitude

The brouhaha between Amarin and its largest shareholder has continued apace, with a smorgasbord of verbal volleys launched against the company, ahead of Amarin’s general meeting of shareholders later this month.

Generic Drugs Market Intelligence

Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.

M & A Deals
See All
UsernamePublicRestriction

Register